F
Fountain Therapeutics
Fountain Therapeutics is discovering and developing treatments for aging-associated diseases
About Fountain Therapeutics
Fountain Therapeutics operates at the intersection of biotechnology and artificial intelligence, focusing on the development of therapeutics that target cellular resilience to combat chronic degenerative diseases. The company leverages its proprietary AI-driven technology, which incorporates advanced machine learning and computer vision, to model and modify cellular health. Fountain's primary clients include healthcare providers, pharmaceutical companies, and research institutions. Operating within the biotech and healthcare markets, Fountain employs a business model centered around the research and development of novel therapeutics, which it monetizes through partnerships, licensing agreements, and direct sales of its therapeutic solutions. The company aims to address the underlying causes of aging-related diseases, offering innovative treatments that improve both the quality and length of life.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- South San Francisco, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 56.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Tech for Biotech and Pharma, Biotech and Pharma, AI Drug Discovery, Hard Tech, Longevity, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2021 | $15M | $60M | Eli Lilly · R42 Group · Khosla Ventures · Nan Fung Life Sciences Real Estate | — |
| SERIES A✓Equity / VC | May 2020 | $6M | $24M | Khosla Ventures · Nan Fung Life Sciences Real Estate | ↗ |
Growth signals
Latest recorded traffic for Fountain Therapeutics is 840 monthly website visits, down 14.3% over the last three months. Fountain Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Pivotal Life Sciences
Nan Fung Life Sciences Real Estate
Khosla Ventures
Eli Lilly
R42 Group
Alexandria Equities
Other known investors1 additional known investor
MBC Biolabs
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fountain Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fountain Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.